ClinicaliQ Trial Snapshot
- A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults — Active Not Recruiting • Oncology • NCT05361434.
- Cabozantinib plus nivolumab as first-line treatment for advanced kidney cancer: real-world safety and effectiveness study.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world clinical practice. The decision to prescribe cabozantinib and nivolumab in combination will be made prior to, and independently from, the decision to enrol the participant in study. Conditions: Advanced Renal Cell Carcinoma Lead Sponsor: Ipsen Planned Enrollment: 311 participants